Moors & Cabot’s Moleculin Biotech MBRX Stock Holding History

Moors & Cabot’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-400	Closed	-$5.3K	–	950
2025 Q3	$5.3K	Buy	+400	New	+$5.4K	﹤0.01%	898

Other funds holding MBRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EFG International Zurich $4.67B AUM

PWPS

Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Moors & Cabot's MBRX Position: Q4 2025 in Review

Moors & Cabot sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 400 shares — an estimated $5.3K sold.

Moors & Cabot first reported a position in MBRX in Q3 2025 and held it in 1 quarter. The position peaked at $5.3K in Q3 2025. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

Moors & Cabot reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
Moors & Cabot sold 400 Moleculin Biotech shares in Q4 2025, an estimated $5.3K.
Moors & Cabot first reported a position in Moleculin Biotech in Q3 2025 and held it in 1 quarter.
Moors & Cabot's Moleculin Biotech position peaked at $5.3K in Q3 2025.
17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on Moors & Cabot's 13F filing for Q4 2025, filed 10 Feb 2026.